Transplantation of Skin Precursor-Derived Schwann Cells Yields Better Locomotor Outcomes and Reduces Bladder Pathology in Rats with Chronic Spinal Cord Injury

Peggy Assinck, 1,2,12 Joseph S. Sparling, 1,2,6 Shaalee Dworski, 9 Greg J. Duncan, 1,3,13 Di L. Wu, 1 Jie Liu, 1 Brian K. Kwon, 1,5 Jeff Biernaskie, 6,7,8 Freda D. Miller, 9,10,11 and Wolfram Tetzlaff 1,3,4,*

1International Collaboration on Repair Discoveries, University of British Columbia, Vancouver, BC, Canada
2Graduate Program in Neuroscience, University of British Columbia, Vancouver, BC, Canada
3Department of Zoology, University of British Columbia, Vancouver, BC, Canada
4Department of Surgery, University of British Columbia, Vancouver, BC, Canada
5Department of Orthopaedics, University of British Columbia, Vancouver, BC, Canada
6Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
7Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada
8Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada
9Neuroscience and Mental Health Program, Hospital for Sick Children, Toronto, ON, Canada
10Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
11Department of Physiology, University of Toronto, Toronto, ON, Canada
12Present address: Center for Regenerative Medicine and Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, Scotland, UK
13Present address: Jungers Center for Neurosciences Research, Department of Neurology, Oregon Health and Science University, Portland, OR, USA

*Correspondence: tetzlaff@icord.org
https://doi.org/10.1016/j.stemcr.2020.05.017

SUMMARY

Cell transplantation for spinal cord injury (SCI) has largely been studied in sub-acute settings within 1–2 weeks of injury. In contrast, here we transplanted skin-derived precursors differentiated into Schwann cells (SKP-SCs) into the contused rat spinal cord 8 weeks post-injury (wpi). Twenty-one weeks later (29 wpi), SKP-SCs were found to have survived transplantation, integrated with host tissue, and mitigated the formation of a dense glial scar. Furthermore, transplanted SKP-SCs filled much of the lesion sites and greatly enhanced the presence of endogenous SCs, which myelinated thousands of sprouting/spared host axons in and around the injury site. In addition, SKP-SC transplantation improved locomotor outcomes and decreased pathological thickening of bladder wall. To date, functional improvements have very rarely been observed with cell transplantation beyond the sub-acute stage of injury. Hence, these findings indicate that skin-derived SCs are a promising candidate cell type for the treatment of chronic SCI.

INTRODUCTION

At present there are no treatments to improve neurologic function of the injured spinal cord, beyond surgical decompression of the spinal cord and rehabilitation therapy. However, more efficacious treatments are urgently needed to promote long-term repair and recovery after spinal cord injury (SCI) to benefit people living with chronic motor, sensory, or autonomic deficits. Cell transplantation has long been considered a promising potential therapy to fill that niche (Assinck et al., 2017a; Tetzlaff et al., 2011). As a candidate cell for SCI treatment, Schwann cells (SCs) possess many desirable properties that are known to promote regeneration and repair after CNS injury by a variety of possible mechanisms (Assinck et al., 2017a; Boerboom et al., 2017). For example, SCs secrete trophic factors (Hoke et al., 2006) and form cellular conduits, similar to the bands of von Büngner found in a regenerating nerve (Bunge, 1994). These cellular conduits align rostro-caudally and attract and guide the growth of axons into and across the site of SCI (Bastidas et al., 2017; Bunge, 2016). In addition, SCs myelinate regenerating and spared CNS axons, provide neuroprotection (Pearse et al., 2018), and promote axonal growth/plasticity and concomitant functional recovery (Bunge et al., 2017; Wiliams and Bunge, 2012). Finally, because SCs can be harvested from peripheral nerves and expanded in vitro, they are well suited for transplantation in the autologous setting.

To generate sufficient cells for autologous clinical application after SCI, peripheral nerve-derived SCs are typically harvested by excising a segment of sural nerve (Anderson et al., 2017). This procedure may result in sensory deficits and carries a risk of painful neuroma formation (Hood et al., 2009). Those deficits/risks could be avoided by using an alternative, more accessible, source of SCs, such as those generated from skin-derived precursors (SKPs). SKPs are resident multipotent stem cells found in the dermis of mammalian skin. Similar to neural crest stem cells, SKPs can be isolated from neonatal/adult rodent and human skin and differentiated in vitro to produce SCs, known as SKP-SCs (Toma et al., 2001; for more citations see Supplemental Experimental Procedures). Given that the harvest of skin is less invasive than that of nerve, SKPs may be a better source of SCs for autologous transplantation after SCI.
Previously, we demonstrated in rats that neonatal SKP-SCs generated from rodent skin and transplanted either acutely (immediately) after cervical crush injury or subacutely (1 week) after thoracic contusion into the site of SCI survived and promoted repair and functional recovery (Biernaskie et al., 2007; Sparling et al., 2015). In addition, we found that acute (immediately post-injury) transplantation of SCs isolated from either neonatal rat nerve or skin-derived precursors promote repair and functional recovery after cervical crush injury (Sparling et al., 2015). Here, we took the next logical step and examined their efficacy in the chronic injury setting. This approach is arguably the most clinically relevant and feasible in clinical trials. Chronic transplantation allows for stabilization of neurological function after SCI and any effects are easier to detect. Delaying treatment also gives time for patients to make informed decisions regarding trial participation (Illes et al., 2011) and for the generation of a sufficient number of cells for autologous transplantation. These considerations have been taken into account in the planning of a recent autologous SC trial in the US (Anderson et al., 2017). However, promoting effective CNS repair in the chronic injury setting is challenging, as the few pre-clinical transplantation studies that have been undertaken with different cell types had no or marginal success to establish functional improvements unless the cells were used in combination with other treatments. Here we transplanted neonatal SKP-SCs generated from rat skin directly into the lesion site 8 weeks after thoracic spinal cord contusions in adult rats. To confirm long-term survival and functional outcomes, and exclude adverse effects, we examined locomotor outcomes up to 27 weeks post-injury (wpi) and anatomical repair at 29 wpi; which is longer than any previous chronic transplantation study. The goal of this experiment was to provide proof-of-principle for the potential of SKP-SCs (without co-treatments) to promote repair and functional recovery in the chronic SCI setting. We report that SKP-SCs survived long-term at the site of chronic SCI, integrated into the host spinal cord and mitigated astrogial scar formation, promoted axonal growth and ensheathment/myelination, and stimulated a massive increase in scar formation, promoted axonal growth and ensheathment into the host spinal cord and mitigated astroglial proliferation (Sparling et al., 2015). We defined the lesion site as tissue with absent or disrupted cytoarchitecture as revealed by GFAP-immunostaining of the host astrocytes (Figure 1B). Importantly, we observe variability from animal to animal in the cavity size, lesion size, existing substrate, and extent of debris at injury epicenter at the time point at which the cells would have been transplanted. At 29 wpi, lesion sites in cell culture medium-injected rats displayed large empty cavities that were walled off by a sharp border of GFAP+ astrocytes (Figure 1C). In contrast, in animals that received SKP-SCs, the lesion site was spanned by bridges of GFP+ cells (Figure 1D). In sections immunostained for GFP to enhance visibility (e.g., Figure 1E) and with nuclear staining, GFP+ cells were present in the spinal cord in all animals, although there was a high degree of variability in cell numbers. Eight of 15 animals that received SKP-SCs contained 70–120,000 GFP+ cells, whereas four animals had 20–70,000 cells, and three rats had fewer than 20,000 cells left in their spinal cords at 21 weeks post-transplantation (Figure 1F). The majority of the SKP-SCs displayed predominant rostro-caudal orientation deviating (on average) not more than 25°–30° from the rostro-caudal axis of the spinal cord and immunostaining for Ki67 indicated minimal proliferation (<0.1%) of the transplanted cells (Figure S1).

SKP-SC Transplantation Increases Intact-Appearing Tissue around the Chronic Injury Site

We defined the lesion site as tissue with absent or disrupted cytoarchitecture as revealed by GFAP-immunostaining of the host astrocytes. Hence, the lesion volume measures the destroyed and/or grossly abnormal spinal cord tissue, including the cavity volume. We saw no differences in lesion volume across the groups (Figure 1G). To assess the amount of intact-appearing tissue surrounding the SCI site, we measured residual GFAP+ spinal cord tissue with intact-appearing cytoarchitecture in the spared rim as well as within the lesion. At 29 wpi, both SKP-SC- and medium-treated animals had significantly more intact-appearing tissue at the lesion epicenter than ToT controls (Figure 1H), indicating an expansion of intact-appearing tissue between 8 and 29 wpi. The amount of intact-appearing tissue was significantly different between the SKP-SC- and medium-treated animals only when high survival of transplanted SKP-SCs was observed (Figure S2; Supplemental Experimental Procedures).

RESULTS

Transplanted SKP-SCs Survive and Bridge the Chronic SCI Lesion

The experimental timeline is summarized in Figure 1A. GFP+ neonatal SKP-SCs were prepared for transplantation and 98.4% of the labeled cells were SCs as demonstrated by colocalization with S100β. Rats received either a neonatal SKP-SC transplantation or a medium injection at 8 weeks post-SCI, underwent regular behavioral tests throughout the study, and were perfused at 21 weeks post-transplant or 29 weeks post-SCI. The time of transplant (ToT) control group was perfused at 8 weeks post-SCI to assess the injury site at the time of treatment. Eight weeks after SCI in the ToT control group, the lesion site was prominent, and filled with residual tissue (much of which is IBA1+) and GFAP+ tissue strands indicative of reactive astrocytes (Figure 1B). Importantly, we observe variability from animal to animal in the cavity size, lesion size, existing substrate, and extent of debris at injury epicenter at the time point at which the cells would have been transplanted. At 29 wpi, lesion sites in cell culture medium-injected rats displayed large empty cavities that were walled off by a sharp border of GFAP+ astrocytes (Figure 1C). In contrast, in animals that received SKP-SCs, the lesion site was spanned by bridges of GFP+ cells (Figure 1D). In sections immunostained for GFP to enhance visibility (e.g., Figure 1E) and with nuclear staining, GFP+ cells were present in the spinal cord in all animals, although there was a high degree of variability in cell numbers. Eight of 15 animals that received SKP-SCs contained 70–120,000 GFP+ cells, whereas four animals had 20–70,000 cells, and three rats had fewer than 20,000 cells left in their spinal cords at 21 weeks post-transplantation (Figure 1F). The majority of the SKP-SCs displayed predominant rostro-caudal orientation deviating (on average) not more than 25°–30° from the rostro-caudal axis of the spinal cord and immunostaining for Ki67 indicated minimal proliferation (<0.1%) of the transplanted cells (Figure S1).
Figure 1. SKP-SC Grafts Survive In Vivo in the Chronically Injured Spinal Cord

(A) Experimental timeline.
(B–D) Photomicrographs of GFAP-immuno-stained contused spinal cords from a Toft control animal (B), a medium-injected control animal (C), and a SKP-SC transplanted animal (D). (B) At 8 wpi, the lesion is filled with both IBA1+ macrophages/microglia (teal in B, arrows) and some residual GFAP+ (red in B and B) host tissue. (C) By 29 wpi, the representative medium control spinal cord has developed a large fluid-filled cavity. (D) SKP-SCs (GFP+) integrate into the lesion sites and bridge the cavity.

(E) High-magnification image of GFP+ SKP-SCs.
(F) SKP-SC counts at 29 wpi for all transplanted rats. Dotted line represents the 70,000-cell level.
(G) The mean lesion volume was similar among the three main groups.
(H) Mean thickness of intact-appearing GFAP+ tissue per group. Note that the Toft control group (8 wpi) had significantly less intact-appearing tissue than the medium (*p = 0.028) and SKP-SC (*p = 0.003) groups (29 wpi). See also Figures S1 and S2.

In (G) and (H): SKP-SC, n = 15; medium, n = 13; Toft, n = 8. Data represented as mean ± SEM. ANOVA with least significant difference (LSD) post-hoc test in (G) and (H). Scale bars: 200 μm in (B)–(D), 20 μm in (B'), and 10 μm in (E).
SKP-SCs Integrate into Spinal Cord Tissue, Mitigate the Formation of the Glial Scar, and Provide a Permissive Substrate for Axon Growth

A major contributor to regeneration failure after SCI is the glial and fibroblastic scar (Dias et al., 2018; Filous and Silver, 2016), although certain aspects of these cellular responses can be beneficial (Anderson et al., 2016). At 8 wpi, a loose mesh of astrocytic processes bordered and extended into the site of SCI, and the lesions were commonly filled with phagocytic cells and residual tissue septae (Figure 2A). By 29 wpi, in the medium control group, most residual tissue had cleared, and the lesions were characterized by “empty” cavities, presumably fluid-filled in vivo, with sharply demarcated borders exhibiting increased GFAP expression (Figures 2B, 2K, and 2L). In contrast, at 29 wpi in the SKP-SC group, host astrocytes extended multiple fine processes into the SKP-SC transplant, particularly at the rostro-caudal boundaries of the lesion site (Figures 2C–2F, 2K, and 2L).

Densitometric analysis (along the white line spanning the cavity-parenchyma interface in Figures 2A–2C) revealed significantly higher GFAP expression in both 29 wpi groups compared with the ToT control group, indicating that reactive gliosis increases over time after SCI (Figures 2G and 2H). Progressive gliosis was mitigated in SKP-SC-treated animals; GFAP expression was reduced compared with medium-only controls (Figures 2G and 2H). In SKP-SC-treated rats, GFAP intensity was high adjacent to regions of cavitation and close to endogenous SCs, and reduced in astrocytes neighboring SKP-SCs (Figure 2J). These effects of SKP-SCs delivered in chronic SCI are similar to our observations following sub-acute transplantation (Biernaskie et al., 2007).

SKP-SCs also provided a more permissive growth substrate. In medium-treated controls, laminin, which is expressed by SCs in peripheral nerves, was typically restricted to blood vessels in the spinal cord and to the host SCs present in the spared tissue margin of the lesion site (Figure 2K, top row). In contrast, in SKP-SC-treated animals, the spinal cord tissue displayed extensive laminin immunoreactivity. Laminin was expressed both within the transplants and in the host tissue bordering the SKP-SC bridges where many of the laminin+ cells were GFP+ endogenous SCs expressing P75NTR (Figure 2K, bottom row).

Integration of SKP-SCs and reduced GFAP immunoreactivity led us to ask whether these differences reflected a change in the inhibitory nature of the glial scar. Inhibitory proteins associated with the glial scar, including neurocan and chondroitin sulfate proteoglycan (CSPG) (CS56 labeling), were expressed in a sharply demarcated boundary around lesion cavities in the medium controls (Figure 2L, top row), but not at the interface of SKP-SC grafts and host tissue (Figure 2L, bottom row) suggestive of a difference in CSPG expression and good integration.

SKP-SCs Promote Growth/Regeneration of Host Axons

To determine whether SKP-SC transplantation enhances axon growth, we first examined spinal cord sections immunolabeled with antibodies against large- and small-caliber axons.
Figure 3. SKP-SCs Promote Axonal Growth/Regeneration into the Chronic Lesion

(A–F) Representative photomicrographs of axons (NF-200/βIII-tubulin) at low (A, C, and E; red) and high (B, D, and F; boxed regions from A, C, and E; white) magnification for the ToFT (8 wpi; A and B), medium (29 wpi; C and D), and SKP-SC (29 wpi; E and F) groups. Blue dotted blue lines in (A), (C), and (E) represent the narrowest point through the lesion where axon counts were conducted shown in (G)–(I); yellow dashed lines in (E) indicate the regions used for axon counts in the rostral, middle, and caudal region of the lesion (Figures S3F–S3I).

(G–I) Average NF-200/βIII-tubulin+ (G), TH+ (H), and SERT+ (I) axon numbers were counted in animals with high graft survival (above the gray line in Figure 1F) within a single confocal plane and compared with controls. (G) Note more than twice as many NF-200/βIII-tubulin+
small-caliber axons (NF-200/βIII-tubulin) in animals with high cell survival (above the gray line in Figure 1F). At 8 wpi, some spared host tissue bridged the lesion site and contained small bundles of axons running in a rostro-caudal orientation (Figures 3A and 3B). By 29 wpi, lesions in medium-treated controls were characterized by tightly demarcated cavities with only rare host tissue septae still containing some axons (Figures 3C and 3D). In contrast, SKP-SC-treated rats with high numbers of surviving SKP-SCs contained many axons extending through SKP-SC bridges, most of which also maintained a rostro-caudal orientation (Figures 3E, 3F, and 3M). The average number of axons within a single confocal plane at the lesion epicenter of the spinal cord (counted along the blue stippled line in Figures 3A, 3C, and 3E; i.e., with the spared rim included) was less than 140 in medium control animals at 29 wpi. There were twice as many axons present after SKP-SC transplantation, mostly in the cell bridges crossing the lesion (Figure 3G).

When we examined specific populations of TH+ and SERT+ axons, more were found at the lesion site in the SKP-SC-treated animals compared with both control groups (Figures 3H–3L, and 3N). Predictably, there were more TH+ and SERT+ axons at the rostral and middle levels of the SKP-SC bridges than the caudal level (counted at the yellow lines shown in Figure 3E), reflecting their origin from the brainstem (Figure S3). Numerous SERT+ and TH+ axons had advanced to the caudal host interface and a small number crossed this interface and entered the caudal spinal cord where they appeared to stop within several hundred microns (Figures 3 and S3). The tortuous appearance of those axons, taken together with the rostro-caudal gradient in their density, suggests that these monoaminergic axons had grown through the SKP-SC bridges but we cannot know for certain whether the axons exited the grafts in the absence of tract tracing. There were no differences in the total number of axons (NF-200/βIII-tubulin) or CGRP+ axons across these rostro-caudal levels (Figure S3). Of note, peptidergic sensory axons expressing substance P or CGRP represented <3% of all the axons in these grafts (Figure S3).

**SKP-SCs Myelinate Axons in the Chronically Injured Spinal Cord**

To determine whether transplanted SKP-SCs myelinated axons, we performed triple labeling for GFP, P0, and axons (NF-200/βIII-tubulin; Figures 4A–4C). We found clear evidence of ensheathment/myelination by SKP-SCs. At 29 wpi, 73% of the SKP-SCs were myelinating, as defined by the formation of a thin GFP+ cytoplasmic layer surrounding P0+ myelin ensheathing a NF-200+ or βIII-tubulin+ axon. Ensheathment/myelination was further confirmed by immuno-labeling for KV1.2 (Figures 4D and 4E), the main potassium channel in the juxtaparanodal axon membrane and CASPR (Figures 4F and 4G), which contributes to the septate junctions between the axon and the paranodal loops of myelin-forming SCs. SKP-SCs and endogenous SCs were generally found in areas with abnormal or absent astrocyte cytoarchitecture, which tended to be devoid of oligodendrocyte myelin. About half (52%) of the axons that had grown into the SKP-SC bridges were wrapped in P0+ myelin.

**SKP-SC Transplantation Augments Spontaneous Repair by Endogenous SCs**

In our previous studies (Biemaskie et al., 2007; Sparling et al., 2015), SKP-SC transplantation prompted an increase in endogenous myelinating SCs occupying the spinal cord. This potential repair mechanism is of interest considering recent work suggesting that centrally derived platelet-derived growth factor receptor alpha+ (PDGFRα) oligodendrocyte precursor cells (OPCs) give rise to SCs after demyelination (Zawadzka et al., 2010) and contusion SCI (Assinck et al., 2017b). To address the endogenous SC response in this study, we examined spinal cord sections for GFP– (i.e., host) myelinating (P0+) and non-myelinating (P75NTR+) SCs.
P0+ SC myelin was often encountered in the lesion walls and the residual tissue strands in and around the lesions in the ToFt (Figure 5A) and medium (Figures 5B and 5F) control groups. However, more P0+ myelin sheaths were found in animals that received SKP-SCs (Figures 5C–5D and 5G). In SKP-SC-treated animals, myelin sheaths were SKP-SC-derived (P0+, GFP+) or host SC-derived (P0+, GFP–); there were more host SC-derived myelin sheaths in SKP-SC-treated animals, even when SKP-SC survival was limited (Figure 5D). There was no correlation between the GFP+ volume and the total P0+ volume (r = 0.030, p = 0.916) in the SKP-SC-treated group. Importantly, this suggests that even the transient presence of SKP-SCs within the injured spinal cord enhanced the endogenous SC response. GFP+ SKP-SCs accounted for a relatively small proportion of the P0 myelin by volume, as only 9.6% of the overall P0 volume in animals that received SKP-SCs overlapped with GFP+ cells (green portion of bar in Figure 5I). Hence, endogenous SCs generated the clear majority of P0 myelin found 29 weeks after SKP-SC transplantation (black portion of bar in Figure 5I).

We also analyzed the location of SC-derived myelin at the level of injury in all groups and found that both the ToFoT and medium control groups had more endogenous SC myelin in the spared tissue than in the lesion site (Figure 5J). In contrast, the SKP-SC group exhibited similar amounts of SC myelin in both locations. SKP-SC-treated animals showed a larger P0 volume inside the lesion site than either control group, and a larger P0 volume outside the lesion compared with the ToFt control group only.

**Figure 4. SKP-SCs Myelinate Axons**

(A–C) Close-up micrograph of an SKP-SC bridge demonstrating the formation of SC myelin (P0, red) around host axons (combined NF-200 and βIII-tubulin, blue) by GFP+ SKP-SCs (green). (C) Note the cell body of the SKP-SC (arrow) and the layers of P0 (arrowhead) sandwiched between the axon and the GFP+ cytoplasm in the outer layer of the SKP-SC.

(D–G) Photomicrographs of axons ensheathed by GFP+ SKP-SCs and immunostained for KV1.2+ potassium channels (D and E) and CASPR (red in F and white in G). Note that SKP-SC-ensheathed axons showed appropriate nodal structures, including nodes of Ranvier (arrows, D–G) with ribbon-like labeling of the paranode by CASPR (arrowheads, F and G) and the juxtaparanode by KV1.2 (arrowheads, D and E) on either side of the node. Scale bars: 20 μm in (A), (B), and (G), 10 μm in (C) and (F), and 5 μm in (D) and (E).
Figure 5. The SKP-SC Group Contains Significantly More SC Myelin and Non-myelinating SCs

(A–D) Overview micrographs of the spinal cords from the ToFT (A), medium-injected (B), and the GFP+ SKP-SC transplanted (C) group immunostained for P0, GFAP, and GFP. (C and D) Note the extensive presence of P0+/GFP− myelin produced by endogenous SCs in the spinal cord of animals with both high (C) (>70,000 SKP-SCs at 29 wpi) or low (D) (<50,000 SKP-SCs at 29 wpi) survival of transplanted SKP-SCs.

(E) Abundant presence of endogenous non-myelinating SCs expressing P75NTR (labelled as P75) in the absence of GFP, often observed in close proximity to GFP+ SKP-SC grafts.

(legend continued on next page)
that the difference between the medium and SKP-SC groups was observed in the weeks after SKP-SC transplantation or showed spontaneous locomotor recovery from the time of (Basso, Beattie, and Bresnahan) scores in both groups also enhanced functional locomotor recovery. The BBB logical repair in chronic SCI, we asked whether these cells

Loeckner Outcomes

Transplantation of SKP-SCs 8 wpi Results in Better Locomotor Outcomes

Having established that SKP-SC transplants promote histological repair in chronic SCI, we asked whether these cells also enhanced functional locomotor recovery. The BBB (Basso, Beattie, and Bresnahan) scores in both groups showed spontaneous locomotor recovery from the time of contusion SCI to the ToT (8 wpi), and no functional decline was observed in the weeks after SKP-SC transplantation or medium injection. A repeated measures ANOVA indicated that the difference between the medium and SKP-SC groups changed over the last 16 weeks of the study with a significant group difference at weeks 19 and 21 (Figure 6A). The amount of P0 expression outside the lesion correlated with the BBB scores at 27 wpi (r = 0.648, p = 0.009).

To complement the open field measurements, we performed Catwalk gait analysis. Average forelimb stride length was ~140 mm pre-injury, dropped to 100 mm post-injury, and remained at that value in the medium group at 26 wpi. In contrast, in rats receiving SKP-SC, stride length recovered partially to 108 mm at 26 wpi. Repeated measures ANOVA revealed that the difference between the medium and SKP-SC groups changed for both forelimb and hindlimb stride length (normalized to each animal’s pre-treatment values) over the last 16 weeks of the study with a significant group difference indicated at each time point denoted with an asterisk (Figures 6B and 6C). Thus, the SKP-SC group maintained longer forelimb and hindlimb stride lengths compared with the medium-only group, which showed a further decline in the hindlimbs (Figure 6C). The injury itself affects hindlimb motor and sensory function but a decrease in hindlimb stride length results in a compensatory decrease in forelimb stride length (Figure 6B). SKP-SC treatment also resulted in a reduced angle of hindlimb paw rotation and a decreased frequency of abnormal gait patterns compared with the medium-only group (Figure S4). No significant differences were detected on hindlimb print width or intensity parameters, the BBB subscore, or the horizontal ladder analysis (Figure S4).

SKP-SC Transplantation Reduces Bladder Pathology Observed after SCI

Autonomic dysfunction is a major concern after SCI and improving bladder function has been ranked a high priority among people living with SCI (Anderson, 2004).

(F) Note the presence of P0+ myelin generated by endogenous (GFP−) SCs in a medium-injected spinal cord.

(G) High-magnification photomicrograph of axons (NF-200/III-tubulin) ensheathed by either GFP+ SKP-SCs (arrow) or GFP− endogenous SCs (arrowhead).

(H) Non-myelinating P75NTR+ SCs derived from transplanted GFP+ SKP-SCs (arrow) within the lesioned spinal cord at 29 wpi.

(I) Quantification of P0+ volumes by treatment groups; the green segment denotes the mean volume of P0+/GFP+ SKP-SCs. The SKP-SC group had significantly greater SC myelin volume (black and green bar combined) than both the medium (***p = 0.005) and the ToT control (**p < 0.001) groups. Importantly, the mean volume of P0+/GFP− endogenous SCs was higher in the SKP-SC group (black portion of bar) than in the medium group (gray bar; *p = 0.038). There was no difference observed between the ToT control and medium control groups (trending toward significance; +p = 0.068).

(J) Distribution of P0+ myelin inside the lesion versus outside the lesion, i.e., in the spared host rim. P0+ volume in the SKP-SC group was greater than the ToT control group both inside (*p = 0.001) and outside (*p = 0.006) of the lesion, and greater than the medium group inside the lesion (*p = 0.005). The ToT control group showed significantly greater P0+ volumes outside the lesion as compared with inside (*p = 0.002); the medium group showed no difference (trending toward significance; +p = 0.067).

(K) The SKP-SC group trended toward larger p75NTR+ volumes versus the medium group (+p = 0.074).

(L) Both the SKP-SC and medium groups showed significantly greater P75NTR+ volume inside the lesion compared with outside (*p = 0.002 and +p = 0.014, respectively; the SKP-SC group approached statistical significance toward a higher p75NTR+ volume versus the medium group inside the lesion only (+p = 0.057). In (I)–(L): SKP-SC, n = 15; medium, n = 15; ToT, n = 8. Individual data points for each animal presented with group medians indicated by solid black lines in (K) and data presented as means ± SEM in (I), (J), and (L). ANOVA with LSD post-hoc test in (I) and (J), paired t test in (J) and (L), MWU in (K), and t test in (L). Scale bars: 200 μm in (A)–(F) and 10 μm in (G) and (H).
(legend on next page)
Although all rats regained spontaneous micturition weeks after injury, ongoing bladder deficits do persist. We can speculate that the T9/T10 contusion injury may damage supraspinal tracts for bladder control and/or a subset of the sympathetic neurons that originate from the spinal cord. We conducted post-hoc histological analysis of the bladder wall to examine the effects of SKP-SC transplantation on bladder pathology. Qualitative examination revealed bladder wall “thickenings” in the medium-treated animals (Figure 6D) that were absent in animals transplanted with SKP-SCs (Figure 6E). Measurements of the thickest point revealed that bladder walls of medium-treated rats were almost twice as thick as SKP-SC-treated rats (Figure 6F). These bladder wall thickenings are typical of bladder-sphincter dyssynergia and/or a lack of inhibitory supraspinal input causing detrusor over-activity (de Groat et al., 1990), suggesting that these issues play less of a role after SKP-SC transplantation. The bladder wall thickness was negatively correlated with both BBB and BBB subscore (Spearman’s rho = −0.414 and −0.425, p = 0.036 and 0.030, respectively, Figures 6G and 6H). For a full list of relevant correlations, see Table S2.

**DISCUSSION**

SKP-SCs transplanted 8 weeks after a thoracic spinal cord contusion survive for more than 5 months at the site of chronic SCI, integrate with spared host tissue, and promote several types of neural repair, including axonal growth/regeneration and SC ensheathment/myelination. Endogenous SCs exhibited a substantial reparative response, which was enhanced by transplanted SKP-SCs. Importantly, SKP-SC transplantation at chronic stages of SCI spurred the growth/regeneration of supraspinal axons into and through the bridges of grafted cells, improved locomotor function, and reduced bladder pathology. The translational relevance of this study is strengthened by our experimental approaches which include (1) the use of a clinically relevant contusion model; (2) the use of a delay in intervention (8 wpi; chronic transplantation), which provides a reasonable time frame for translation with regards to optimal clinical trial design; and (3) the decision to follow the animals for more than 5 months after intervention allowing us to define ongoing histological and behavioral changes. Together, our findings suggest that SKP-SCs represent a promising intervention for SCI, with the potential to confer benefits in the chronic setting.

Our estimates indicate that up to 12% of the transplanted SKP-SCs survived in the host spinal cord for 21 weeks post-transplantation. However, this likely represents an underestimate, as we did not account for cells lost during the transplantation process, which may have been ~20% according to previous findings (Hill et al., 2006). The extensive integration of SKP-SCs observed at the endpoint was unexpected and prompted us to analyze the injury site at 8 wpi in the TofT control group to better understand the environment encountered by the transplanted cells.

At 8 wpi the lesion was full of mononuclear cells (many of which were IBA1+), lacked a dense glial scar, and contained numerous GFAP+ processes as well as small bundles of axons that ran rostro-caudal through the site of injury on either side of the ventral fissure. We observed considerable variability in lesion size, cavity size, and the amount of...
existing substrate in the TofT control group. The substantial number of rostro-caudal oriented spared axons, together with astrocytic processes, may have provided a suitable substrate for SKP-SCs and endogenous SCs in this study aiding to bridge the lesion sites.

Axons are known to grow into and within nerve-derived SC grafts, but they tend to struggle to leave those grafts and grow back into the astrocyte-rich host parenchyma also known as “off-ramp” problem (Williams and Bunge, 2012). Despite the disruption of normal GFAP cytoarchitecture at the lesion site, SKP-SC and astrocyte processes often intermingled at the transplant-host interface and it was noted that SKP-SCs trended towards inducing less GFAP expression in adjacent astrocytes than endogenous SCs near the injury site. This arrangement appeared to provide a permissive growth environment for axons entering and exiting the grafts. Importantly, such permissive SC graft/spinal cord interfaces have only been observed previously for nerve-derived SC transplants combined with Matrigel (Williams et al., 2015) or engineered to overexpress GDNF (Deng et al., 2013). Of the thousands of axons found in SKP-SC bridges, ~40% were of brainstem origin (based on immunolabeling for TH and SERT). The presence of TH+ axons at the caudal transplant-host interface was surprising, considering that the growth/regeneration of supraspinal axons in response to nerve-derived SCs typically requires the addition of co-treatments (i.e., other cells, drugs, biomaterials, or trophic support; for review see Assinck et al., 2017a; Bunge, 2016; Tetzlaff et al., 2011). While this may reflect an advantage of SKP-SCs over nerve-derived SCs, it is important to note that, in the absence of tract tracing, the exiting and connectivity of those TH+ axons, and thus their contribution to functional recovery, remained uncertain in this study.

The increase in intact-appearing rim tissue between 8 and 29 wpi was unexpected and may be due in part to the release of a second wave of injury-related factors (e.g., cytokines) triggered by the transplantation surgery or increases in spinal cord area associated with growth. Given the state of the lesion site at 8 wpi, it remains unclear whether the thickening of the rim over time was the result of neuroprotective or reparative mechanisms, as the sparing and remyelination of denuded axons and the growth and myelination of new axons may both have contributed. Resident OPCs can give rise to new oligodendrocytes, and in the mouse 30% of the myelin is de novo generated by 12 wpi (Assinck et al., 2017b); combined with the increase in P0+ SC myelin during that time, this could explain the increased rim thickness observed. The fact that rim thickness was more pronounced in the SKP-SC large transplant subgroup at 29 wpi may be due to increased axonal growth/regeneration, as that group had a higher number of axons in intact-appearing tissue than either the medium-treated or TofT control groups. In addition, replacement of oligodendrocyte myelin by SC myelin may have contributed to thicker rims (particularly in the SKP-SC group), as SC myelin is known to occupy more space than oligodendrocyte myelin (Kocsis and Waxman, 2007). Whether oligodendrocyte remyelination plays a role in locomotor recovery remains unclear in this study, but a direct role seems unlikely as genetic inhibition of remyelination in mice did not impede spontaneous functional recovery in a comparable moderate contusion injury model (Duncan et al., 2018).

The enhanced endogenous SC response in SKP-SC transplanted animals suggests that the presence, even if transient, of SKP-SCs results in more endogenous myelinating and non-myelinating SCs at the injury epicenter. This agrees with data from experiments transplanting nerve-derived SCs (Biernaskie et al., 2007; Hill et al., 2006), olfactory ensheathing cells (OECs) (Ramer et al., 2004), bone marrow stromal cells (Lu et al., 2007), and fibroblasts (Sparling et al., 2015) after SCI. Our fate-mapping work indicates that most of the SCs observed in the spinal cord of adult mice after contusion injury are derived from CNS OPCs (Assinck et al., 2017b). In agreement, OPCs can become SCs after transplantation (Talbott et al., 2006) or chemical demyelination of the spinal cord in mice, where this phenomenon was primarily observed in areas lacking astrocytes (Zawadzka et al., 2010). Cell-specific deletion of STAT3 in astrocytes decreased remyelination by oligodendrocytes in favor of SCs (Monteiro de Castro et al., 2015), and MBP/WNT signaling within the perivascular niche supports OPC differentiation into SCs after chemical demyelination (Ulanska-Poutanen et al., 2018). Hence, our data suggest that transplanted SKP-SCs may promote the generation of SCs from OPCs in the chronically injured spinal cord.

Few pre-clinical cell transplantation studies have been performed in the chronic stage of spinal cord contusion or compression injuries and efficacy usually required co-treatments (Tetzlaff et al., 2011). No behavioral improvements have been observed after chronic transplantation without co-treatments of, e.g., neural stem cells (Jin et al., 2016; Karimi-Abdolrezaee et al., 2010; Nutt et al., 2013; Parr et al., 2007; Suzuki et al., 2017), OECs (Barakat et al., 2005), or human embryonic stem cell-derived OPCs (Keirstead et al., 2005) when those cells have been applied on their own in “chronic” pre-clinical SCI studies using rodents (i.e., ~2 months or more after injury). Indeed, mouse neural stem/progenitor cells transplanted 7 weeks after clip compression injury in rats required combinatorial administration of chondroitinase ABC, minocycline, plus a cocktail of growth factors to achieve notable functional improvements (Karimi-Abdolrezaee et al., 2010). Similarly, other co-treatments, such as γ-secretase inhibitors, treadmill training, and chondroitinase ABC are improving the
outcomes of transplantation in the early chronic stages (Nori et al., 2018; Okubo et al., 2018; Tashiro et al., 2016). Taken together, the available data suggest that realizing functional improvements after long treatment delays is extremely challenging, particularly for cellular therapies delivered without co-treatments. With that in mind, the functional outcomes seen here with a single-cell therapy, SKP-SCs, applied at 8 wpi were highly encouraging. To our knowledge, only a couple of other chronic (approximately 6–8 wpi) spinal cord contusion studies have demonstrated any functional efficacy for a single-cell therapy in the absence of co-treatments (Barakat et al., 2005; Okubo et al., 2018). One of these studies used SCs generated from peripheral nerves (Barakat et al., 2005). In addition to effects in the open field, our study found benefits in gait performance and reduced signs of bladder pathology for SKP-SC-treated animals.

The present work may represent an important step toward the development of an autologous or allogeneic transplantation protocol to treat chronic SCI with SCs generated from the skin, a highly accessible and available alternative to peripheral nerves. The number of people living with chronic SCI far outweighs the number who might benefit from acute treatments. The functional improvements and mitigation of SCI-related bladder pathology seen in this study after chronic transplantation of SKP-SC are encouraging as any long-term functional gain may have a positive impact on the health of the aging chronic SCI population. Nerve-derived SCs and SKP-SCs at the transcriptome level show only discrete differences between these cell types (Krause et al., 2014), adding credence to the notion that SKP-SCs should perform similarly to their nerve-derived counterparts in clinical trials. However, pre-clinical experiments that address the safety and efficacy of human neonatal/adult SKP-SCs are required to determine whether autologous SKP-SC transplantation merits trials in humans with SCI.

**EXPERIMENTAL PROCEDURES**

For the full details of all procedures, please see the Supplemental Experimental Procedures. In brief, 47 adult female Sprague-Dawley rats (Charles River, Wilmington, MA) were injured/treated. All procedures were approved by the Hospital for Sick Children Research Institute and the University of British Columbia Animal Care Committee in accordance with the guidelines of the Canadian Council on Animal Care. Behavioral and histological assessments were conducted and analyzed by individuals blinded to treatment. All group comparisons involved parametric or non-parametric analyses. The significance level for all tests was p < 0.05; two-tailed.

**SCI, Cell Culture, and Transplantation**

All rats received a 200-kdyne thoracic contusion SCI at the T9/T10 vertebral level delivered via the Infinite Horizon Impactor (Preci-}

---

**Functional Assessment**

Functional locomotor abilities were assessed using the open field BBB score and subscore, footprint analysis, and the irregular horizontal ladder.

**Histological Assessment**

SKP-SC- and medium-treated rats were perfused with 4% paraformaldehyde at 29 wpi and the TofT control group was perfused at 8 wpi. Following cryoprotection and freezing, the spinal cords were sectioned longitudinally (each slide containing 10 sagittal sections spaced 200–220 μm apart) and the bladders were cut transversely (each slide containing two cross-sections of the bladder wall), both on a cryostat at 20 μm thickness. Using immunohistochemistry (see Table S1 for list of antibodies), all 10 longitudinal sections were analyzed to calculate lesion volume, transplant volume, P0 volume, P75NTR volume, average intact-appearing tissue, average tissue width, and GFAP intensity. Axon counts and GFP+ graft densities were performed on a subset of spinal cord sections. For more details, see Supplemental Experimental Procedures.

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at https://doi.org/10.1016/j.stemcr.2020.05.017.

**AUTHOR CONTRIBUTIONS**

P.A., J.S.S., J.B., F.D.M., and W.T. designed the research. P.A., J.S.S., S.D., G.J.D., and J.L. performed the experiments. P.A., G.J.D., and D.L.W. analyzed the data. P.A. and W.T. wrote the paper with editorial contributions from J.S.S., G.J.D., B.K.K., J.B., and F.D.M.

**ACKNOWLEDGMENTS**

The technical assistance of Yuan Jiang, Clarrie Lam, Michael J. Lee, Ailblish Skinner, and Lisa Anderson is gratefully acknowledged. We also thank Dr. Leanne Ramer, Dr. Jason Plemel, and Dr. Brett J. Hilton for their valuable advice. We also acknowledge Dr. J. Trimmer for providing us with nodal antibodies. Graphical abstract created with BioRender.com. We apologize to our colleagues who were not cited due to space limitations. This work was supported by Canadian Institutes of Health Research (CIHR) (130475) and a CIHR Regenerative Medicine and Nanotechnology grant (RM92085) and the Canadian Stem Cell Network (SCN CT8). P.A. received a CIHR Masters and Doctoral Award; S.D. held a CIHR Training Program in Regenerative Medicine studentship; G.J.D. was supported by an MS Society of Canada Doctoral Scholarship; J.B. held a CIHR
post-doctoral fellowship; B.K.K. holds the Canada Research Chair (CRC) in SCI; F.D.M. is a CRC and a Howard Hughes Medical Institute International Research Scholar; W.T. holds the John and Penny Ryan British Columbia Leadership Chair in Spinal Cord Research.

Received: January 31, 2017
Revised: May 20, 2020
Accepted: May 21, 2020
Published: June 18, 2020

REFERENCES

Anderson, K.D. (2004). Targeting recovery: priorities of the spinal cord-injured population. J. Neurotrauma 21, 1371–1383.

Anderson, K.D., Guest, J.D., Dietrich, W.D., Bartlett Bunge, M., Curiel, R., Dididze, M., Green, B.A., Khan, A., Pearse, D.D., Saraf-Lavi, E., et al. (2017). Safety of autologous human Schwann cell transplantation in subacute thoracic spinal cord injury. J. Neurotrauma 34, 2950–2963.

Anderson, M.A., Burda, J.E., Ren, Y., Ao, Y., O’Shea, T.M., Kawaguchi, R., Coppola, G., Khakh, B.S., Deming, T.J., and Sofroniew, M.V. (2016). Astrocyte scar formation aids central nervous system axon regeneration. Nature 532, 195–200.

Assinck, P., Duncan, G.J., Hilton, B.J., Plemel, J.R., and Tetzlaff, W. (2017a). Cell transplantation therapy for spinal cord injury. Nat. Neurosci. 20, 637–647.

Assinck, P., Duncan, G.J., Plemel, J.R., Lee, M.J., Stratton, J.A., Manesh, S.B., Liu, J., Ramer, L.M., Kang, S.H., Bergles, D.E., et al. (2017b). Myelinogenic plasticity of oligodendrocyte precursor cells following spinal cord contusion injury. J. Neurosci. 37, 8635–8654.

Barakat, D.J., Gagliani, S.M., Neravetla, S.R., Sanchez, A.R., Andrade, C.M., Pressman, Y., Puzis, R., Garg, M.S., Bunge, M.B., and Pearse, D.D. (2005). Survival, integration, and axon growth support of glia transplanted into the chronically contused spinal cord. Cell Transplant 14, 225–240.

Bastidas, J., Athauda, G., De La Cruz, G., Chan, W.M., Golshani, R., Berrocal, Y., Henao, M., Lalwani, A., Mannoji, C., Assi, M., et al. (2017). Human Schwann cells exhibit long-term cell survival, are not tumorigenic and promote repair when transplanted into the contused spinal cord. Glia 65, 1278–1301.

Biernaskie, J., Sparling, J.S., Liu, J., Shannon, C.P., Plemel, J.R., Xie, Y., Miller, E.D., and Tetzlaff, W. (2007). Skin-derived precursors generate myelinating Schwann cells that promote remyelination and functional recovery after contusion spinal cord injury. J. Neurosci. 27, 9545–9559.

Biernaskie, J.A., McKenzie, I.A., Toma, J.G., and Miller, E.D. (2006). Isolation of skin-derived precursors (SKPs) and differentiation and enrichment of their Schwann cell progeny. Nat. Protoc. 1, 2803–2812.

Boerboom, A., Dion, V., Chariot, A., and Franzen, R. (2017). Molecular mechanisms involved in Schwann cell plasticity. Front. Mol. Neurosci. 10, 38.

Bunge, M.B. (2016). Efficacy of Schwann cell transplantation for spinal cord repair is improved with combinatorial strategies. J. Physiol. 594, 3533–3538.

Bunge, M.B., Monje, P.V., Khan, A., and Wood, P.M. (2017). From transplanting Schwann cells in experimental rat spinal cord injury to their transplantation into human injured spinal cord in clinical trials. Prog. Brain Res. 231, 107–133.

Bunge, R.P. (1994). The role of the Schwann cell in trophic support and regeneration. J. Neurol. 242, S19–S21.

de Groat, W.C., Katayama, M., Hisamitsu, T., Cheng, C.L., Ma, C.P., Thor, K., Steers, W., and Roppolo, J.R. (1990). Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J. Auton. Nerv Syst. 30 Suppl, S71–S77.

Deng, L.X., Deng, P., Ruan, Y., Xu, Z.C., Liu, N.K., Wen, X., Smith, G.M., and Xu, X.M. (2013). A novel growth-promoting pathway formed by GDNF-overexpressing Schwann cells promotes proprioan axonal regeneration, synapse formation, and partial recovery of function after spinal cord injury. J. Neurosci. 33, 5655–5667.

Dias, D.O., Kim, H., Holl, D., Werne Solneström, B., Lundeberg, J., Carlen, M., Goritz, C., and Frisen, J. (2018). Reducing pericyte-derived scarring promotes recovery after spinal cord injury. Cell 173, 153–165 e122.

Duncan, G.J., Manesh, S.B., Hilton, B.J., Assinck, P., Liu, J., Moulson, A., Plemel, J.R., and Tetzlaff, W. (2018). Locomotor recovery following contusive spinal cord injury does not require oligodendrocyte remyelination. Nat. Commun. 9, 3066.

Filous, A.R., and Silver, J. (2016). Targeting astrocytes in CNS injury and disease: a translational research approach. Prog. Neurobiol. 144, 173–187.

Hill, C.E., Moon, L.D., Wood, P.M., and Bunge, M.B. (2006). Labeled Schwann cell transplantation: cell loss, host Schwann cell replacement, and strategies to enhance survival. Glia 53, 338–343.

Hoke, A., Redett, R., Hameed, H., Jari, R., Zhou, C., Li, Z.B., Griffin, J.W., and Brushart, T.M. (2006). Schwann cells express motor and sensory phenotypes that regulate axon regeneration. J. Neurosci. 26, 9646–9655.

Hood, B., Levene, H.B., and Levi, A.D. (2009). Transplantation of autologous Schwann cells for the repair of segmental peripheral nerve defects. Neurosurg. Focus 26, E4.

Illes, J., Reimer, J.C., and Kwon, B.K. (2011). Stem cell clinical trials for spinal cord injury: readiness, reluctance, redefinition. Stem Cell Rev. Rep. 7, 997–1005.

Jin, Y., Bouver, Y., Shumsky, J.S., Haas, C., and Fischer, I. (2016). Transplantation of neural progenitor cells in chronic spinal cord injury. Neuroscience 320, 69–82.

Karimi-Abdolrezae, S., Efekharpar, E., Wang, J., Schut, D., and Fehlings, M.G. (2010). Synergistic effects of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. J. Neurosci. 30, 1657–1676.

Keirstead, H.S., Nistor, G., Bernal, G., Totoiu, M., Cloutier, F., Sharp, K., and Steward, O. (2005). Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. 25, 4694–4705.
Kocsis, J.D., and Waxman, S.G. (2007). Schwann cells and their precursors for repair of central nervous system myelin. Brain 130, 1978–1980.

Krause, M.P., Dworski, S., Feinberg, K., Jones, K., Johnston, A.P., Paul, S., Paris, M., Peles, E., Bagli, D., Forrest, C.R., et al. (2014). Direct genesis of functional rodent and human Schwann cells from skin mesenchymal precursors. Stem Cell Reports 3, 85–100.

Lu, P., Jones, L.L., and Tuszynski, M.H. (2007). Axon regeneration through scars and into sites of chronic spinal cord injury. Exp. Neurol. 203, 8–21.

Monteiro de Castro, G., Deja, N.A., Ma, D., Zhao, C., and Franklin, R.J. (2015). Astrocyte activation via Stat3 signaling determines the balance of oligodendrocyte versus Schwann cell remyelination. Am. J. Pathol. 185, 2431–2440.

Nori, S., Khazaei, M., Ahuja, C.S., Yokota, K., Ahlfors, J.E., Liu, Y., Wang, J., Shibata, S., Chio, J., Hettiarratchi, M.H., et al. (2018). Human oligodendrogenic neural progenitor cells delivered with chondroitinase ABC facilitate functional repair of chronic spinal cord injury. Stem Cell Reports 11, 1433–1448.

Nutt, S.E., Chang, E.A., Suhr, S.T., Schlosser, L.O., Mondello, S.E., Moritz, C.T., Cibelli, J.B., and Horner, P.J. (2013). Caudalized human iPSC-derived neural progenitor cells produce neurons and glia but fail to restore function in an early chronic spinal cord injury model. Exp. Neurol. 248, 491–503.

Okubo, T., Nagoshi, N., Kohyama, J., Tsuji, O., Shinozaki, M., Shibata, S., Kase, Y., Matsumoto, M., Nakamura, M., and Okano, H. (2018). Treatment with a gamma-secretase inhibitor promotes functional recovery in human iPSC-derived transplants for chronic spinal cord injury. Stem Cell Reports 11, 1416–1432.

Parr, A.M., Kulbatski, I., and Tator, C.H. (2007). Transplantation of adult rat spinal cord stem/progenitor cells for spinal cord injury. J. Neurotrauma 24, 835–845.

Pearse, D.D., Bastidas, J., Izabel, S.S., and Ghosh, M. (2018). Schwann cell transplantation subdues the pro-inflammatory innate immune cell response after spinal cord injury. Int. J. Mol. Sci. 19, 2550.

Ramer, L.M., Au, E., Richter, M.W., Liu, J., Tetzlaff, W., and Roskams, A.J. (2004). Peripheral olfactory ensheathing cells reduce scar and cavity formation and promote regeneration after spinal cord injury. J. Comp. Neurol. 473, 1–15.

Sparling, J.S., Bretzner, F., Biernaskie, J., Assinck, P., Jiang, Y., Arisato, H., Plunet, W.T., Borisoff, J., Liu, J., Miller, F.D., et al. (2015). Schwann cells generated from neonatal skin-derived precursors or neonatal peripheral nerve improve functional recovery after acute transplantation into the partially injured cervical spinal cord of the rat. J. Neurosci. 35, 6714–6730.

Suzuki, H., Ahuja, C.S., Salewski, R.P., Li, L., Satkunendrarajah, K., Nagoshi, N., Shibata, S., and Fehlings, M.G. (2017). Neural stem cell mediated recovery is enhanced by Chondroitinase ABC treatment in chronic spinal cord injury. PLoS One 12, e0182339.

Talbott, J.F., Cao, Q., Enzmann, G.U., Benton, R.L., Achim, V., Cheng, X.X., Mills, M.D., Rao, M.S., and Whittemore, S.R. (2006). Schwann cell-like differentiation by adult oligodendrocyte precursor cells following engraftment into the demyelinated spinal cord is BMP-dependent. Glia 54, 147–159.

Tashiro, S., Nishimura, S., Iwai, H., Sugai, K., Zhang, L., Shinozaki, M., Iwanami, A., Toyama, Y., Liu, M., Okano, H., et al. (2016). Functional recovery from neural stem/progenitor cell transplantation combined with treadmill training in mice with chronic spinal cord injury. Sci. Rep. 6, 30898.

Tetzlaff, W., Okon, E.B., Karimi-Abdolrezaei, S., Hill, C.E., Sparling, J.S., Plemel, J.R., Plunet, W.T., Tsai, E.C., Baptiste, D., Smithson, L.J., et al. (2011). A systematic review of cellular transplantation therapies for spinal cord injury. J. Neurotrauma 28, 1611–1682.

Toma, J.G., Akhavan, M., Fernandes, K.J., Barnabe-Heider, F., Sadikot, A., Kaplan, D.R., and Miller, F.D. (2001). Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat. Cell Biol. 3, 778–784.

Ulanska-Poutanen, J., Miecikowski, J., Zhao, C., Konarzewska, K., Kaza, B., Pohl, H.B., Bugajski, L., Kaminska, B., Franklin, R.J., and Zawadzka, M. (2018). Injury-induced perivascular niche supports alternative differentiation of adult rodent CNS progenitor cells. eLife 7, e30325.

Williams, R.R., and Bunge, M.B. (2012). Schwann cell transplantation: a repair strategy for spinal cord injury? Prog. Brain Res. 201, 295–312.

Williams, R.R., Henao, M., Pearse, D.D., and Bunge, M.B. (2015). Permissive Schwann cell graft/spinal cord interfaces for axon regeneration. Cell Transplant 24, 115–131.

Zawadzka, M., Rivers, L.E., Fancy, S.P., Zhao, C., Tripathi, R., Jämen, F., Young, K., Goncharevich, A., Pohl, H., Rizzi, M., et al. (2010). CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 6, 578–590.